Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitis
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000007020
- Lead Sponsor
- ung Oncology Group in Kyushu, Japan (LOGIK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 32
Not provided
1)Prior elrotinib treatment with the exception of elrotinib discontinuation for four weeks or more at study enrollment. 2)Active interstitial pneumonia or pulmonary fibrosis on chest CT scan 3)Severe drug allergy 4)Prior radiotherapy to chest within 2 weeks 5)Massive pleural effusion, ascites or pericardial effusion 6)Active infection 7)Continuous watery diarrhea 8)Intestinal paralysis or ileus 9)Symptomatic ophthalmologic disease 10)Current or previous (within the last 1 year) gastrointestinal perforation 11)Severe ulcer 12)Severe cardiac disease 13)Severe psychological disease 14)Pregnant or breast-feeding females or those who declined contraception 15)Inappropriate patients for this study judged by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Overall survival Meningitis progression free survival Adverse event Examination of cerebrospinal fluid Performance status Quality of life